Mammography screening: A major issue in medicine

European Journal of Cancer

Volumn 90, Issue , 2018, Pages 34-62

  Autier, Philippe ^a   Boniol, Mathieu ^a  

^a INTERNATIONAL PREVENTION RESEARCH INSTITUTE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ERROR; EVALUATION AND FOLLOW UP; HIGH RISK POPULATION; HUMAN; MAMMOGRAPHY; MORTALITY RISK; NEUROBLASTOMA; PRECANCER; PRIORITY JOURNAL; RADICAL MASTECTOMY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; STATISTICAL MODEL; UTERINE CERVIX CANCER; BREAST TUMOR; DIAGNOSTIC IMAGING; EARLY CANCER DIAGNOSIS; FEMALE; HEALTH SERVICE; INCIDENCE; PROCEDURES;

BREAST NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; INCIDENCE; MAMMOGRAPHY; MEDICAL OVERUSE;

EID: 85038909732     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2017.11.002     Document Type: Article

References (280)

1. Autier, P., Boniol, M., La Vecchia, C., Vatten, L., Gavin, A., Hery, C., et al. Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality database. BMJ, 341, 2010, c3620.
2. DeSantis, C.E., Bray, F., Ferlay, J., Lortet-Tieulent, J., Anderson, B.O., Jemal, A., International variation in female breast cancer incidence and mortality rates. Cancer Epidemiol Biomarkers Prev 24:10 (2015), 1495–1506.
3. Bosetti, C., Bertuccio, P., Levi, F., Chatenoud, L., Negri, E., La Vecchia, C., The decline in breast cancer mortality in Europe: an update (to 2009). Breast 21:1 (2012), 77–82.
4. Tabar, L., Fagerberg, C.J., Gad, A., Baldetorp, L., Holmberg, L.H., Grontoft, O., et al. Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the breast cancer screening working group of the Swedish national board of health and welfare. Lancet 1:8433 (1985), 829–832.
5. Shapiro, S., Venet, W., Strax, P., Venet, L., Roeser, R., Selection, follow-up, and analysis in the Health Insurance Plan Study: a randomized trial with breast cancer screening. Natl Cancer Inst Monogr 67 (1985), 65–74.
6. Nystrom, L., Andersson, I., Bjurstam, N., Frisell, J., Nordenskjold, B., Rutqvist, L.E., Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet 359:9310 (2002), 909–919.
7. Miller, A.B., To, T., Baines, C.J., Wall, C., The Canadian National Breast Screening Study-1: breast cancer mortality after 11 to 16 years of follow-up. A randomized screening trial of mammography in women age 40 to 49 years. Ann Intern Med 137:5 Part 1 (2002), 305–312.
8. Miller, A.B., To, T., Baines, C.J., Wall, C., Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women aged 50-59 years. J Natl Cancer Inst 92:18 (2000), 1490–1499.
9. Gotzsche, P.C., Olsen, O., Is screening for breast cancer with mammography justifiable?. Lancet 355:9198 (2000), 129–134.
10. Morrison, A.S., Intermediate determinants of mortality in the evaluation of screening. Int J Epidemiol 20:3 (1991), 642–650.
11. World Health Organization, Cancer IAfRo. Cancer: causes, occurrence and control. 1990, International Agency for Research on Cancer, Lyon, France.
12. Cole, P., Morrison, A.S., Basic issues in population screening for cancer. J Natl Cancer Inst 64:5 (1980), 1263–1272.
13. Greenwald, P., Sondik, E.J., Young, J.L. Jr., Emerging roles for cancer registries in cancer control. Yale J Biol Med 59:5 (1986), 561–566.
14. Pell, J.P., Haw, S., Cobbe, S., Newby, D.E., Pell, A.C., Fischbacher, C., et al. Smoke-free legislation and hospitalizations for acute coronary syndrome. N Engl J Med 359:5 (2008), 482–491.
15. Schoen, R.E., Pinsky, P.F., Weissfeld, J.L., Yokochi, L.A., Church, T., Laiyemo, A.O., et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med 366:25 (2012), 2345–2357.
16. Elmunzer, B.J., Hayward, R.A., Schoenfeld, P.S., Saini, S.D., Deshpande, A., Waljee, A.K., Effect of flexible sigmoidoscopy-based screening on incidence and mortality of colorectal cancer: a systematic review and meta-analysis of randomized controlled trials. Plos Med, 9(12), 2012, e1001352.
17. Holme, O., Bretthauer, M., Fretheim, A., Odgaard-Jensen, J., Hoff, G., Flexible sigmoidoscopy versus faecal occult blood testing for colorectal cancer screening in asymptomatic individuals. Cochrane Database Syst Rev, 9, 2013, CD009259.
18. Sankaranarayanan, R., Nene, B.M., Shastri, S.S., Jayant, K., Muwonge, R., Budukh, A.M., et al. HPV screening for cervical cancer in rural India. N Engl J Med 360:14 (2009), 1385–1394.
19. Laara, E., Day, N.E., Hakama, M., Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes. Lancet 1:8544 (1987), 1247–1249.
20. Day, N.E., Screening for cancer of the cervix. J Epidemiol Community Health 43:2 (1989), 103–106.
21. Sigurdsson, K., Sigvaldason, H., Longitudinal trends in cervical histological lesions (CIN 2–3 + ): a 25-year overview. Acta Obstet Gynecol Scand 85:3 (2006), 359–365.
22. Edwards, B.K., Ward, E., Kohler, B.A., Eheman, C., Zauber, A.G., Anderson, R.N., et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 116:3 (2010), 544–573.
23. Cho, H., Mariotto, A.B., Schwartz, L.M., Luo, J., Woloshin, S., When do changes in cancer survival mean progress? The insight from population incidence and mortality. J Natl Cancer Inst Monogr 2014:49 (2014), 187–197.
24. Bulk, S., Visser, O., Rozendaal, L., Verheijen, R.H., Meijer, C.J., Cervical cancer in The Netherlands 1989-1998: decrease of squamous cell carcinoma in older women, increase of adenocarcinoma in younger women. Int J Cancer 113:6 (2005), 1005–1009.
25. Cramer, D.W., The role of cervical cytology in the declining morbidity and mortality of cervical cancer. Cancer 34:6 (1974), 2018–2027.
26. Miller, A.B., Lindsay, J., Hill, G.B., Mortality from cancer of the uterus in Canada and its relationship to screening for cancer of the cervix. Int J Cancer 17:5 (1976), 602–612.
27. Johannesson, G., Geirsson, G., Day, N., Tulinius, H., Screening for cancer of the uterine cervix in Iceland 1965–1978. Acta Obstet Gynecol Scand 61:3 (1982), 199–203.
28. Ait Ouakrim, D., Pizot, C., Boniol, M., Malvezzi, M., Boniol, M., Negri, E., et al. Trends in colorectal cancer mortality in Europe: retrospective analysis of the WHO mortality database. BMJ, 351, 2015, h4970.
29. Liu, S., Semenciw, R., Probert, A., Mao, Y., Cervical cancer in Canada: changing patterns in incidence and mortality. Int J Gynecol Cancer 11:1 (2001), 24–31.
30. Blanks, R.G., Moss, S.M., McGahan, C.E., Quinn, M.J., Babb, P.J., Effect of NHS breast screening programme on mortality from breast cancer in England and Wales, 1990-8: comparison of observed with predicted mortality. BMJ 321:7262 (2000), 665–669.
31. Woods, W.G., Tuchman, M., Robison, L.L., Bernstein, M., Leclerc, J.M., Brisson, L.C., et al. Screening for neuroblastoma is ineffective in reducing the incidence of unfavourable advanced stage disease in older children. Eur J Cancer 33:12 (1997), 2106–2112.
32. Woods, W.G., Gao, R.N., Shuster, J.J., Robison, L.L., Bernstein, M., Weitzman, S., et al. Screening of infants and mortality due to neuroblastoma. N Engl J Med 346:14 (2002), 1041–1046.
33. Schilling, F.H., Spix, C., Berthold, F., Erttmann, R., Fehse, N., Hero, B., et al. Neuroblastoma screening at one year of age. N Engl J Med 346:14 (2002), 1047–1053.
34. Tsubono, Y., Hisamichi, S., A halt to neuroblastoma screening in Japan. N Engl J Med 350:19 (2004), 2010–2011.
35. Ioka, A., Inoue, M., Yoneda, A., Nakamura, T., Hara, J., Hashii, Y., et al. Effects of the cessation of mass screening for neuroblastoma at 6 months of age: a population-based study in Osaka, Japan. J Epidemiol 26:4 (2016), 179–184.
36. International Agency for Research on Cancer, Breast cancer screening. 2002, IARCPress.
37. Autier, P., Hery, C., Haukka, J., Boniol, M., Byrnes, G., Advanced breast cancer and breast cancer mortality in randomized controlled trials on mammography screening. J Clin Oncol 27:35 (2009), 5919–5923.
38. Smith, R.A., Duffy, S.W., Gabe, R., Tabar, L., Yen, A.M., Chen, T.H., The randomized trials of breast cancer screening: what have we learned?. Radiol Clin North Am 42:5 (2004), 793–806.
39. Day, N.E., Williams, D.R., Khaw, K.T., Breast cancer screening programmes: the development of a monitoring and evaluation system. Br J Cancer 59:6 (1989), 954–958.
40. Fracheboud, J., de Gelder, R., Otto, S.J., van Ineveld, B.M., Otten, J.D.M., Broeders, M.J.M., et al. National evaluation of breast cancer screening in The Netherlands 1990-2007. 2009, National Evaluation Team for Breast Cancer Screening (NETB), The Netherlands.
41. Fracheboud, J., Otto, S.J., van Dijck, J.A., Broeders, M.J., Verbeek, A.L., de Koning, H.J., et al. Decreased rates of advanced breast cancer due to mammography screening in The Netherlands. Br J Cancer 91:5 (2004), 861–867.
42. Otto, S.J., Fracheboud, J., Looman, C.W.N., Broeders, M.J.M., Boer, R., Hendriks, J.H.C.L., et al. Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: a systematic review. Lancet 361:9367 (2003), 1411–1417.
43. NETB, NETfBcs. National evaluation of breast screening in The Netherlands, 1990-2011/12. Rotterdam, Nijmegen. 2014.
44. Autier, P., Boniol, M., Koechlin, A., Pizot, C., Boniol, M., Effectiveness of and overdiagnosis from mammography screening in the Netherlands: population based study. BMJ, 359, 2017, j5224.
45. Autier, P., Boniol, M., Middleton, R., Dore, J.F., Hery, C., Zheng, T., et al. Advanced breast cancer incidence following population-based mammographic screening. Ann Oncol 22:8 (2011), 1726–1735.
46. Bleyer, A., Welch, H.G., Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med 367:21 (2012), 1998–2005.
47. de Glas, N.A., de Craen, A.J., Bastiaannet, E., Op 't Land, E.G., Kiderlen, M., van de Water, W., et al. Effect of implementation of the mass breast cancer screening programme in older women in The Netherlands: population based study. Bmj, 349, 2014, g5410.
48. Autier, P., Boniol, M., The incidence of advanced breast cancer in the West Midlands, United Kingdom. Eur J Cancer Prev 21:3 (2012), 217–221.
49. Nederend, J., Duijm, L.E., Voogd, A.C., Groenewoud, J.H., Jansen, F.H., Louwman, M.W., Trends in incidence and detection of advanced breast cancer at biennial screening mammography in The Netherlands: a population based study. Breast Cancer Res, 14(1), 2012, R10.
50. Lousdal, M.L., Kristiansen, I.S., Moller, B., Stovring, H., Trends in breast cancer stage distribution before, during and after introduction of a screening programme in Norway. Eur J Public Health 24:6 (2014), 1017–1022.
51. Johnson, R.H., Chien, F.L., Bleyer, A., Incidence of breast cancer with distant Involvement among women in the United States, 1976 to 2009. JAm Med Assoc 309:8 (2013), 800–805.
52. Esserman, L., Shieh, Y., Thompson, I., Rethinking screening for breast cancer and prostate cancer. Jama 302:15 (2009), 1685–1692.
53. Jorgensen, K., Gøtzsche, P.C., Kalager, M., Zahl, P., Breast cancer screening in Denmark: a cohort study of tumor size and overdiagnosis. Ann Intern Med 166:5 (2017 Mar 7), 313–323.
54. Welch, H.G., Gorski, D.H., Albertsen, P.C., Trends in metastatic breast and prostate cancer —lessons in cancer dynamics. N. Engl JMed 373:18 (2015), 1685–1687.
55. Di Meglio, A., Freedman, R.A., Lin, N.U., Barry, W.T., Metzger-Filho, O., Keating, N.L., et al. Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis. Breast Cancer Res Treat 157:3 (2016), 587–596.
56. Autier, P., Boniol, M., Gavin, A., Vatten, L.J., Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database. BMJ, 343, 2011, d4411.
57. Jorgensen, K.J., Zahl, P.H., Gotzsche, P.C., Breast cancer mortality in organised mammography screening in Denmark: comparative study. Bmj, 340, 2010, c1241.
58. Broeders, M.J., Peer, P.G., Straatman, H., Beex, L.V., Hendriks, J.H., Holland, R., et al. Diverging breast cancer mortality rates in relation to screening? A comparison of Nijmegen to Arnhem and The Netherlands, 1969-1997. Int J Cancer 92:2 (2001), 303–308.
59. Autier, P., Koechlin, A., Smans, M., Vatten, L., Boniol, M., Mammography screening and breast cancer mortality in Sweden. J Natl Cancer Inst 104:14 (2012), 1080–1093.
60. Bleyer, A., Baines, C., Miller, A.B., Impact of screening mammography on breast cancer mortality. Int J Cancer 138:8 (2016), 2003–2012.
61. Harding, C., Pompei, F., Burmistrov, D., Welch, H.G., Abebe, R., Wilson, R., Breast cancer screening, incidence, and mortality across US counties. JAMA Intern Med 175:9 (2015), 1483–1489.
62. Lousdal, M.L., Kristiansen, I.S., Moller, B., Stovring, H., Effect of organised mammography screening on stage-specific incidence in Norway: population study. Br J Cancer 114:5 (2016), 590–596.
63. Park, J.H., Anderson, W.F., Gail, M.H., Improvements in US breast cancer survival and proportion explained by tumor size and estrogen-receptor status. J Clin Oncol 33:26 (2015), 2870–2876.
64. Bare, M., Tora, N., Salas, D., Sentis, M., Ferrer, J., Ibanez, J., et al. Mammographic and clinical characteristics of different phenotypes of screen-detected and interval breast cancers in a nationwide screening program. Breast Cancer Res Treat 154:2 (2015), 403–415.
65. Caldarella, A., Puliti, D., Crocetti, E., Bianchi, S., Vezzosi, V., Apicella, P., et al. Biological characteristics of interval cancers: a role for biomarkers in the breast cancer screening. J Cancer Res Clin Oncol 139:2 (2013), 181–185.
66. Arpino, G., Bardou, V.J., Clark, G.M., Elledge, R.M., Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 6:3 (2004), 1–8.
67. Drukker, C.A., Schmidt, M.K., Rutgers, E.J., Cardoso, F., Kerlikowske, K., Esserman, L.J., et al. Mammographic screening detects low-risk tumor biology breast cancers. Breast Cancer Res Treat 144:1 (2014), 103–111.
68. Joensuu, H., Lehtimaki, T., Holli, K., Elomaa, L., Turpeenniemi-Hujanen, T., Kataja, V., et al. Risk for distant recurrence of breast cancer detected by mammography screening or other methods. Jama 292:9 (2004), 1064–1073.
69. Gilliland, F.D., Joste, N., Stauber, P.M., Hunt, W.C., Rosenberg, R., Redlich, G., et al. Biologic characteristics of interval and screen-detected breast cancers. J Natl Cancer Inst 92:9 (2000), 743–749.
70. Kirsh, V.A., Chiarelli, A.M., Edwards, S.A., O'Malley, F.P., Shumak, R.S., Yaffe, M.J., et al. Tumor characteristics associated with mammographic detection of breast cancer in the Ontario breast screening program. J Natl Cancer Inst 103:12 (2011), 942–950.
71. Crosier, M., Scott, D., Wilson, R.G., Griffiths, C.D., May, F.E., Westley, B.R., Differences in Ki67 and c-erbB2 expression between screen-detected and true interval breast cancers. Clin Cancer Res 5:10 (1999), 2682–2688.
72. Foulkes, W.D., Smith, I.E., Reis-Filho, J.S., Triple-negative breast cancer. N Engl J Med 363:20 (2010), 1938–1948.
73. Mook, S., Van 't Veer, L.J., Rutgers, E.J., Ravdin, P.M., van de Velde, A.O., van Leeuwen, F.E., et al. Independent prognostic value of screen detection in invasive breast cancer. J Natl Cancer Inst 103:7 (2011), 585–597.
74. Lehtimaki, T., Lundin, M., Linder, N., Sihto, H., Holli, K., Turpeenniemi-Hujanen, T., et al. Long-term prognosis of breast cancer detected by mammography screening or other methods. Breast Cancer Res, 13(6), 2011, R134.
75. Klemi, P., Joensuu, H., Toikkanen, S., Tuominen, J., Rasanen, O., Tyrkko, J., et al. Aggressiveness of breast cancers found with and without screening. BMJ 304 (1992), 467–469.
76. Hayse, B., Hooley, R.J., Killelea, B.K., Horowitz, N.R., Chagpar, A.B., Lannin, D.R., Breast cancer biology varies by method of detection and may contribute to overdiagnosis. Surgery 160:2 (2016), 454–462.
77. Narod, S.A., Dube, M.P., Re: Biologic characteristics of interval and screen-detected breast cancers. J Natl Cancer Inst 93:2 (2001), 151–152.
78. Holmberg, L.H., Tabar, L., Adami, H.O., Bergstrom, R., Survival in breast cancer diagnosed between mammographic screening examinations. Lancet 2:8497 (1986), 27–30.
79. Kalager, M., Tamimi, R.M., Bretthauer, M., Adami, H.O., Prognosis in women with interval breast cancer: population based observational cohort study. BMJ, 345, 2012, e7536.
80. Kessler, L.G., Feuer, E.J., Brown, M.L., Projections of the breast cancer burden to U.S. women: 1990-2000. Prev Med 20:1 (1991), 170–182.
81. Rossouw, J.E., Anderson, G.L., Prentice, R.L., LaCroix, A.Z., Kooperberg, C., Stefanick, M.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. Jama 288:3 (2002), 321–333.
82. Zahl, P.-H., Gøtzsche, P.C., Mæhlen, J., Natural history of breast cancers detected in the Swedish mammography screening programme: a cohort study. Lancet Oncol 12:12 (2011), 1118–1124.
83. Zahl, P.H., Overdiagnosis of invasive breast cancer due to mammography screening. Ann Intern Med 157:3 (2012), 220–221.
84. Welch, H.G., Black, W.C., Using autopsy series to estimate the disease ‘reservoir’ for ductal carcinoma in situ of the breast: how much more breast cancer can we find?. Ann Intern Med 127:11 (1997), 1023–1028.
85. Bhathal, P.S., Brown, R.W., Lesueur, G.C., Russell, I.S., Frequency of benign and malignant breast lesions in 207 consecutive autopsies in Australian women. Br J Cancer 51:2 (1985), 271–278.
86. Baasch, M., Nielsen, S.F., Engholm, G., Lund, K., Breast cancer incidence subsequent to surgical reduction of the female breast. Br J Cancer 73:7 (1996), 961–963.
87. Sorin, T., Fyad, J.P., Delay, E., Rouanet, P., Rimareix, F., Houpeau, J.L., et al. Occult cancer in specimens of reduction mammaplasty aimed at symmetrization. A multicentric study of 2718 patients. Breast 24:3 (2015), 272–277.
88. Esserman, L., When less is better, but physicians are afraid not to Intervene. JAMA Intern Med 176:7 (2016), 888–889.
89. Nielsen, M., Thomsen, J.L., Primdahl, S., Dyreborg, U., Andersen, J.A., Breast cancer and atypia among young and middle-aged women: a study of 110 medicolegal autopsies. Br J Cancer 56:6 (1987), 814–819.
90. Esserman, L., Yau, C., Rethinking the standard for ductal carcinoma in situ treatment. JAMA Oncol 1:7 (2015), 881–883.
91. Duffy, S.W., Tabar, L., Vitak, B., Day, N.E., Smith, R.A., Chen, H.H., et al. The relative contributions of screen-detected in situ and invasive breast carcinomas in reducing mortality from the disease. Eur J Cancer 39:12 (2003), 1755–1760.
92. Punglia, R.S., Schnitt, S.J., Weeks, J.C., Treatment of ductal carcinoma in situ after excision: would a prophylactic paradigm be more appropriate?. J Natl Cancer Inst 105:20 (2013), 1527–1533.
93. Elmore, J.G., Nelson, H.D., Pepe, M.S., Longton, G.M., Tosteson, A.N., Geller, B., et al. Variability in pathologists' interpretations of individual breast biopsy slides: a population perspective. Ann Intern Med 164:10 (2016), 649–655.
94. Narod, S.A., Iqbal, J., Giannakeas, V., Sopik, V., Sun, P., Breast cancer mortality after a diagnosis of ductal carcinoma in situ. JAMA Oncol 1:7 (2015), 888–896.
95. Wapnir, I.L., Dignam, J.J., Fisher, B., Mamounas, E.P., Anderson, S.J., Julian, T.B., et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. JNCI JNatl Cancer Inst 103:6 (2011), 478–488.
96. Darby, S.C., Ewertz, M., McGale, P., Bennet, A.M., Blom-Goldman, U., Bronnum, D., et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 368:11 (2013), 987–998.
97. Cardoso, F., van't Veer, L.J., Bogaerts, J., Slaets, L., Viale, G., Delaloge, S., et al. 70-Gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 375:8 (2016), 717–729.
98. Sparano, J.A., Gray, R.J., Makower, D.F., Pritchard, K.I., Albain, K.S., Hayes, D.F., et al. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 373:21 (2015), 2005–2014.
99. Etzioni, R., Gulati, R., Mallinger, L., Mandelblatt, J., Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening. Ann Intern Med 158:11 (2013), 831–838.
100. Biesheuvel, C., Barratt, A., Howard, K., Houssami, N., Irwig, L., Effects of study methods and biases on estimates of invasive breast cancer overdetection with mammography screening: a systematic review. Lancet Oncol 8:12 (2007), 1129–1138.
101. Jorgensen, K.J., Gotzsche, P.C., Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. BMJ, 339, 2009, b2587.
102. Jorgensen, K.J., Zahl, P.H., Gotzsche, P.C., Overdiagnosis in organised mammography screening in Denmark. A comparative study. BMC Womens Health, 9, 2009, 36.
103. Kalager, M., Adami, H.O., Bretthauer, M., Tamimi, R.M., Overdiagnosis of invasive breast cancer due to mammography screening: results from the Norwegian screening program. Ann Intern Med 156:7 (2012), 491–499.
104. Ripping, T.M., Verbeek, A.L., Fracheboud, J., de Koning, H.J., van Ravesteyn, N.T., Broeders, M.J., Overdiagnosis by mammographic screening for breast cancer studied in birth cohorts in The Netherlands. Int J Cancer 137:4 (2015), 921–929.
105. Independent, U.K., Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet 380:9855 (2012), 1778–1786.
106. Moss, S.M., Cuckle, H., Evans, A., Johns, L., Waller, M., Bobrow, L., Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial. Lancet 368:9552 (2006), 2053–2060.
107. Moss, S.M., Wale, C., Smith, R., Evans, A., Cuckle, H., Duffy, S.W., Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age Trial at 17 years’ follow-up: a randomised controlled trial. Lancet Oncol 16:9 (2015), 1123–1132.
108. Autier, P., Breast cancer: doubtful health benefit of screening from 40 years of age. Nat Rev Clin Oncol 12:10 (2015), 570–572.
109. The Research Council of Norway, Research-based evaluation of the Norwegian breast cancer screening Program, final report: evaluation division for society and health., 2015 www.forskningsradet.no/publikasjoner.
110. Bleyer, A., Welch, H.G., Effect of screening mammography on breast cancer incidence. N Engl J Med, 368(7), 2013, 679.
111. Gotzsche, P.C., Jorgensen, K.J., Screening for breast cancer with mammography. Cochrane Database Syst Rev, 6, 2013, Cd001877.
112. Nederend, J., Duijm, L.E., Louwman, M.W., Roumen, R.M., Jansen, F.H., Voogd, A.C., Trends in surgery for screen-detected and interval breast cancers in a national screening programme. Br J Surg 101:8 (2014), 949–958.
113. Tataru, D., Robinson, D., Moller, H., Davies, E., Trends in the treatment of breast cancer in Southeast England following the introduction of national guidelines. J Public Health (Oxf) 28:3 (2006), 215–217.
114. Dragun, A.E., Huang, B., Tucker, T.C., Spanos, W.J., Increasing mastectomy rates among all age groups for early stage breast cancer: a 10-year study of surgical choice. Breast J 18:4 (2012), 318–325.
115. Mahmood, U., Hanlon, A.L., Koshy, M., Buras, R., Chumsri, S., Tkaczuk, K.H., et al. Increasing national mastectomy rates for the treatment of early stage breast cancer. Ann Surg Oncol 20:5 (2013), 1436–1443.
116. Kummerow, K.L., Du, L., Penson, D.F., Shyr, Y., Hooks, M.A., Nationwide trends in mastectomy for early-stage breast cancer. JAMA Surg 150:1 (2015), 9–16.
117. Houssami, N., Turner, R., Morrow, M., Preoperative magnetic resonance imaging in breast cancer: meta-analysis of surgical outcomes. Ann Surg 257:2 (2013), 249–255.
118. Parsyan, A., Alqahtani, A., Mesurolle, B., Meterissian, S., Impact of preoperative breast MRI on surgical decision making and clinical outcomes: a systematic review. World J Surg 37:9 (2013), 2134–2139.
119. Veronesi, U., Stafyla, V., Luini, A., Veronesi, P., Breast cancer: from ‘maximum tolerable’ to ‘minimum effective’ treatment. Front Oncol, 2, 2012, 125.
120. Brennan, M.E., Houssami, N., Lord, S., Macaskill, P., Irwig, L., Dixon, J.M., et al. Magnetic resonance imaging screening of the contralateral breast in women with newly diagnosed breast cancer: systematic review and meta-analysis of incremental cancer detection and impact on surgical management. J Clin Oncol 27:33 (2009), 5640–5649.
121. Wang, S.Y., Long, J.B., Killelea, B.K., Evans, S.B., Roberts, K.B., Silber, A., et al. Preoperative breast magnetic resonance imaging and contralateral breast cancer occurrence among older women with breast cancer. J Clin Oncol 34:4 (2016), 321–328.
122. Woods, W.G., Substitute ‘prostate cancer’ for ‘neuroblastoma’?. J Clin Oncol 20:5 (2002), 1154–1155.
123. Moyer, V.A., Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 157:2 (2012), 120–134.
124. Paci, E., Group, E.W., Summary of the evidence of breast cancer service screening outcomes in Europe and first estimate of the benefit and harm balance sheet. J Med Screen 19:Suppl. 1 (2012), 5–13.
125. Verbeek, A.L., Broeders, M.J., Evaluation of cancer service screening: case referent studies recommended. Stat Methods Med Res 19:5 (2010), 487–505.
126. Lauby-Secretan, B., Loomis, D., Straif, K., Breast-cancer screening–viewpoint of the IARC working group. N Engl J Med, 373(15), 2015, 1479.
127. Chu, K.C., Miller, B.A., Feuer, E.J., Hankey, B.F., A method for partitioning cancer mortality trends by factors associated with diagnosis: an application to female breast cancer. J Clin Epidemiol 47:12 (1994), 1451–1461.
128. Njor, S., Nystrom, L., Moss, S., Paci, E., Broeders, M., Segnan, N., et al. Breast cancer mortality in mammographic screening in Europe: a review of incidence-based mortality studies. J Med Screen 19:Suppl. 1 (2012), 33–41.
129. Olsen, A.H., Lynge, E., Njor, S.H., Kumle, M., Waaseth, M., Braaten, T., et al. Breast cancer mortality in Norway after the introduction of mammography screening. Int J Cancer 132:1 (2013), 208–214.
130. Hellquist, B.N., Duffy, S.W., Abdsaleh, S., Bjorneld, L., Bordas, P., Tabar, L., et al. Effectiveness of population-based service screening with mammography for women ages 40 to 49 years: evaluation of the Swedish Mammography Screening in Young Women (SCRY) cohort. Cancer 117:4 (2011), 714–722.
131. Tabar, L., Yen, M.-F., Vitak, B., Chen, H.-H.T., Smith, R.A., Duffy, S.W., Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet 361:9367 (2003), 1405–1410.
132. Parvinen, I., Heinavaara, S., Anttila, A., Helenius, H., Klemi, P., Pylkkanen, L., Mammography screening in three Finnish residential areas: comprehensive population-based study of breast cancer incidence and incidence-based mortality 1976–2009. Br J Cancer 112:5 (2015), 918–924.
133. Johns, L.E., Coleman, D.A., Swerdlow, A.J., Moss, S.M., Effect of population breast screening on breast cancer mortality up to 2005 in England and Wales: an individual-level cohort study. Br J Cancer 116:2 (2017), 246–252.
134. Kalager, M., Zelen, M., Langmark, F., Adami, H.O., Effect of screening mammography on breast-cancer mortality in Norway. N Engl J Med 363:13 (2010), 1203–1210.
135. Jonsson, H., Nyström, L., Törnberg, S., Lenner, P., Service screening with mammography of women aged 50–69 years in Sweden: effects on mortality from breast cancer. J Med Screen 8 (2001), 152–160.
136. Jonsson, H., Nyström, L., Törnberg, S., Lundgren, B., Lenner, P., Service screening with mammography. Long-term effects on breast cancer mortality in the county of Gävleborg. SwedBreast 12:3 (2003), 183–193.
137. Swedish Organised Service Screening Evaluation G, Reduction in breast cancer mortality from organized service screening with mammography: 1. Further confirmation with extended data. Cancer Epidemiol Biomarkers Prev 15:1 (2006), 45–51.
138. Otto, S.J., Fracheboud, J., Verbeek, A.L., Boer, R., Reijerink-Verheij, J.C., Otten, J.D., et al. Mammography screening and risk of breast cancer death: a population-based case–control study. Cancer Epidemiol Biomarkers Prev 21:1 (2012), 66–73.
139. Paap, E., Verbeek, A., Puliti, D., Broeders, M., Paci, E., Minor influence of self-selection bias on the effectiveness of breast cancer screening in case–control studies in The Netherlands. J Med Screen 18:3 (2011), 142–146.
140. Paap, E., Holland, R., den Heeten, G.J., van Schoor, G., Botterweck, A.A., Verbeek, A.L., et al. A remarkable reduction of breast cancer deaths in screened versus unscreened women: a case-referent study. Cancer Causes Control 21:10 (2010), 1569–1573.
141. Nickson, C., Mason, K.E., English, D.R., Kavanagh, A.M., Mammographic screening and breast cancer mortality: a case–control study and meta-analysis. Cancer Epidemiol Biomarkers Prev 21:9 (2012), 1479–1488.
142. Fielder, H.M., Warwick, J., Brook, D., Gower-Thomas, K., Cuzick, J., Monypenny, I., et al. A case–control study to estimate the impact on breast cancer death of the breast screening programme in Wales. J Med Screen 11:4 (2004), 194–198.
143. Jorgensen, K.J., Flawed methods explain the effect of mammography screening in Nijmegen. Br J Cancer 105:4 (2011), 592–593 author reply 594–595.
144. Janzon, L., Andersson, I., The Malmömamography screening trial. Miller, A., Chamberlain, J., Day, N.E., (eds.) Cancer screening, 1991, Cambridge University Press, Cambridge, 37–44.
145. Phillips, N., Coldman, A., Comparison of nonbreast cancer incidence, survival and mortality between breast screening program participants and nonparticipants. Int J Cancer 122:1 (2008), 197–201.
146. Zackrisson, S., Janzon, L., Manjer, J., Andersson, I., Improved survival rate for women with interval breast cancer - results from the breast cancer screening programme in Malmo, Sweden 1976-1999. J Med Screen 14:3 (2007), 138–143.
147. Feig, S.A., Overdiagnosis of breast cancer at screening is clinically insignificant. Acad Radiol 22:8 (2015), 961–966.
148. Kopans, D.B., Smith, R.A., Duffy, S.W., Mammographic screening and ‘overdiagnosis’. Radiology 260:3 (2011), 616–620.
149. Paci, E., Miccinesi, G., Puliti, D., Baldazzi, P., De Lisi, V., Falcini, F., et al. Estimate of overdiagnosis of breast cancer due to mammography after adjustment for lead time. A service screening study in Italy. Breast Cancer Res, 8(6), 2006, R68.
150. Olsen, A.H., Agbaje, O.F., Myles, J.P., Lynge, E., Duffy, S.W., Overdiagnosis, sojourn time, and sensitivity in the Copenhagen mammography screening program. Breast J 12:4 (2006), 338–342.
151. de Gelder, R., Heijnsdijk, E.A., van Ravesteyn, N.T., Fracheboud, J., Draisma, G., de Koning, H.J., Interpreting overdiagnosis estimates in population-based mammography screening. Epidemiol Rev 33:1 (2011), 111–121.
152. Duffy, S.W., Tabar, L., Olsen, A.H., Vitak, B., Allgood, P.C., Chen, T.H., et al. Absolute numbers of lives saved and overdiagnosis in breast cancer screening, from a randomized trial and from the Breast Screening Programme in England. J Med Screen 17:1 (2010), 25–30.
153. Carter, J.L., Coletti, R.J., Harris, R.P., Quantifying and monitoring overdiagnosis in cancer screening: a systematic review of methods. BMJ, 350, 2015, g7773.
154. Zahl, P.H., Suhrke, P., Jorgensen, K.J., Overdiagnosis of breast cancer in Norway: what have the authors adjusted for?. Int J Cancer 133:11 (2013), 2754–2755.
155. Zahl, P.H., Jorgensen, K.J., Gotzsche, P.C., Overestimated lead times in cancer screening has led to substantial underestimation of overdiagnosis. Br J Cancer 109:7 (2013), 2014–2019.
156. Humphrey, L.L., Helfand, M., Chan, B.K., Woolf, S.H., Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 137:5 Part 1 (2002), 347–360.
157. Twombly, R., American researchers question effect of Scandinavian mammography debate. J Natl Cancer Inst 99:16 (2007), 1216–1217.
158. Ebrahim, S., Sohani, Z.N., Montoya, L., Agarwal, A., Thorlund, K., Mills, E.J., et al. Reanalyses of randomized clinical trial data. JAMA 312:10 (2014), 1024–1032.
159. Autier, P., Boniol, M., Smans, M., Sullivan, R., Boyle, P., Statistical analyses in Swedish randomised trials on mammography screening and in other randomised trials on cancer screening: a systematic review. J R Soc Med 108:11 (2015), 440–450.
160. Editor's Note, JNatl Cancer Inst, 100(2), 2008, 156.
161. Tarone, R.E., The excess of patients with advanced breast cancer in young women screened with mammography in the Canadian National Breast Screening Study. Cancer 75:4 (1995), 997–1003.
162. Bailar, J.C. 3rd, MacMahon, B., Randomization in the Canadian national breast screening study: a review for evidence of subversion. CMAJ 156:2 (1997), 193–199.
163. Cohen, M.M., Kaufert, P.A., MacWilliam, L., Tate, R.B., Using an alternative data source to examine randomization in the Canadian national breast screening study. J Clin Epidemiol 49:9 (1996), 1039–1044.
164. Kopans, D.B., Feig, S.A., The Canadian national breast screening study: a critical review. AJR Am J Roentgenol 161:4 (1993), 755–760.
165. Autier, P., Boniol, M., Smans, M., Sullivan, R., Boyle, P., Observed and predicted risk of breast cancer death in randomized trials on breast cancer screening. PLoS One, 11(4), 2016, e0154113.
166. Boniol, M., Autier, P., Gandini, S., Melanoma mortality following skin cancer screening in Germany. BMJ Open, 5, 2015.
167. Stang, A., Jockel, K.H., Does skin cancer screening save lives? A detailed analysis of mortality time trends in Schleswig-Holstein and Germany. Cancer, 2015.
168. Djulbegovic, M., Beyth, R.J., Neuberger, M.M., Stoffs, T.L., Vieweg, J., Djulbegovic, B., et al. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. Bmj, 341, 2010, c4543.
169. Schroder, F.H., Hugosson, J., Roobol, M.J., Tammela, T.L., Ciatto, S., Nelen, V., et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 366:11 (2012), 981–990.
170. Schroder, F.H., Hugosson, J., Roobol, M.J., Tammela, T.L., Ciatto, S., Nelen, V., et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:13 (2009), 1320–1328.
171. Hugosson, J., Carlsson, S., Aus, G., Bergdahl, S., Khatami, A., Lodding, P., et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 11:8 (2010), 725–732.
172. Bjurstam, N., Bjorneld, L., Warwick, J., Sala, E., Duffy, S.W., Nystrom, L., et al. The Gothenburg breast screening trial. Cancer 97:10 (2003), 2387–2396.
173. Frisell, J., Lidbrink, E., Hellstrom, L., Rutqvist, L.E., Folluwup after 11 years - update of mortality results in the Stockholm mammographic screening trial. Breast Cancer Res Treat 45 (1997), 263–270.
174. Tabar, L., Vitak, B., Chen, H.H., Duffy, S.W., Yen, M.F., Chiang, C.F., et al. The Swedish Two-County Trial twenty years later. Updated mortality results and new insights from long-term follow-up. Radiol Clin North Am 38:4 (2000), 625–651.
175. Autier, P., Boniol, M., Smans, M., Sullivan, R., Boyle, P., Screening mammography: Authors' response to Nystrom and Tabar and colleagues. J R Soc Med 108:11 (2015), 431–432.
176. Berry, D.A., Benefits and risks of screening mammography for women in their forties: a statistical appraisal. J Natl Cancer Inst 90:19 (1998), 1431–1439.
177. Tabar, L., Fagerberg, G., Duffy, S.W., Day, N.E., The Swedish two county trial of mammographic screening for breast cancer: recent results and calculation of benefit. J Epidemiol Community Health 43:2 (1989), 107–114.
178. Shapiro, S., Evidence on screening for breast cancer from a randomized trial. Cancer 39:6 Suppl (1977), 2772–2782.
179. Shapiro, S., Venet, W., Strax, P., Venet, L., Current results of the breast cancer screening randomized trial: the health insurance plan (HIP) of greater New York study. Screening for breast cancer, 1987, Huber Toronto, Toronto, 3–15.
180. Fox, M.S., On the diagnosis and treatment of breast cancer. Jama 241:5 (1979), 489–494.
181. Miller, A.B., Screening for breast cancer with mammography. Lancet, 358(9299), 2001, 2164 author reply 2167–2168.
182. Tabar, L., Fagerberg, G., Duffy, S.W., Day, N.E., Gad, A., Grontoft, O., Update of the Swedish Two-County program of mammographic screening for breast cancer. Radiol Clin North Am 30:1 (1992), 187–210.
183. Duffy, S.W., Tabar, L., Fagerberg, G., Gad, A., Grontoft, O., South, M.C., et al. Breast screening, prognostic factors and survival–results from the Swedish two county study. Br J Cancer 64:6 (1991), 1133–1138.
184. Andersson, I., Aspegren, K., Janzon, L., Landberg, T., Lindholm, K., Linell, F., et al. Mammographic screening and mortality from breast cancer: the Malmo mammographic screening trial. BMJ 297:6654 (1988), 943–948.
185. Biesheuvel, C., Czene, K., Orgeas, C.C., Hall, P., The role of mammography screening attendance and detection mode in predicting breast cancer survival-is there added prognostic value?. Cancer Epidemiol 35:6 (2011), 545–550.
186. Peer, P.G., Holland, R., Hendriks, J.H., Mravunac, M., Verbeek, A.L., Age-specific effectiveness of the Nijmegen population-based breast cancer-screening program: assessment of early indicators of screening effectiveness. J Natl Cancer Inst 86:6 (1994), 436–441.
187. Fink, R., Shapiro, S., Lewison, J., The reluctant participant in a breast cancer screening program. Rep Pub Health 83:6 (1968), 479–490.
188. Moss, S., Waller, M., Anderson, T.J., Cuckle, H., Trial Management, G., Randomised controlled trial of mammographic screening in women from age 40: predicted mortality based on surrogate outcome measures. Br J Cancer 92:5 (2005), 955–960.
189. Narod, S.A., On being the right size: a reappraisal of mammography trials in Canada and Sweden. Lancet, 349(9068), 1997 1846.
190. Tabar, L., Fagerberg, G., Chen, H.H., Duffy, S.W., Smart, C.R., Gad, A., et al. Efficacy of breast cancer screening by age. New results from the Swedish Two-County Trial. Cancer 75:10 (1995), 2507–2517.
191. Ong, M.S., Mandl, K.D., National expenditure for false-positive mammograms and breast cancer overdiagnoses estimated at $4 billion a year. Health Aff (Millwood) 34:4 (2015), 576–583.
192. Biller-Andorno, N., Juni, P., Abolishing mammography screening programs? A view from the Swiss Medical Board. N Engl J Med 370:21 (2014), 1965–1967.
193. Jatoi, I., The impact of advances in treatment on the efficacy of mammography screening. Prev Med 53:3 (2011), 103–104.
194. Fletcher, S.W., Breast cancer screening: a 35-year perspective. Epidemiol Rev 33:1 (2011), 165–175.
195. USPSTF, Screening for testicular cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med 154:7 (2011), 483–486.
196. Autier, P., Efficient treatments reduce the cost-efficiency of breast cancer screening. Ann Intern Med 164:4 (2016), 297–298.
197. Birnbaum, J., Gadi, V.K., Markowitz, E., Etzioni, R., The effect of treatment advances on the mortality results of breast cancer screening trials: a microsimulation model. Ann Intern Med 164:4 (2016), 236–243.
198. Lieberman, D., Colorectal cancer screening with colonoscopy. JAMA Intern Med 176:7 (2016), 903–904.
199. IARC, Cervix cancer screening, vol. 10, 2005, IARC Handbooks of Cancer Prevention.
200. Fearon, E.R., Vogelstein, B., A genetic model for colorectal tumorigenesis. Cell 61:5 (1990), 759–767.
201. Bernards, R., Weinberg, R.A., Metastasis genes: a progression puzzle. Nature, 418(6900), 2002 823–823.
202. Welch, H.G., Search and destroy–the right cancer strategy for Europeans?. Eur J Cancer 41:5 (2005), 660–663.
203. Tabar, L., Duffy, S.W., Vitak, B., Chen, H.H., Prevost, T.C., The natural history of breast carcinoma: what have we learned from screening?. Cancer 86:3 (1999), 449–462.
204. Tubiana, M., Koscielny, S., The natural history of breast cancer: implications for a screening strategy. Int J Radiat Oncol Biol Phys 19:5 (1990), 1117–1120.
205. Tubiana, M., Koscielny, S., Natural history of human breast cancer: recent data and clinical implications. Breast Cancer Res Treat 18:3 (1991), 125–140.
206. Hellman, S., Karnofsky Memorial Lecture. Natural history of small breast cancers. J Clin Oncol 12:10 (1994), 2229–2234.
207. Welch, H.G., Black, W.C., Overdiagnosis in cancer. J Natl Cancer Inst 102:9 (2010), 605–613.
208. Perou, C.M., Sorlie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., Rees, C.A., et al. Molecular portraits of human breast tumours. Nature 406:6797 (2000), 747–752.
209. Sorlie, T., Perou, C.M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:19 (2001), 10869–10874.
210. van de Vijver, M.J., He, Y.D., van't Veer, L.J., Dai, H., Hart, A.A., Voskuil, D.W., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:25 (2002), 1999–2009.
211. Lannin, D.R., Wang, S., Are small breast cancers good because they are small or small because they are good?. N Engl J Med 376:23 (2017), 2286–2291.
212. Berry, D.A., Cronin, K.A., Plevritis, S.K., Fryback, D.G., Clarke, L., Zelen, M., et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:17 (2005), 1784–1792.
213. Collaborators CISMNBC, Executive summary. JNCI Monogr 2006:36 (2006), 1–2.
214. Kramer, B.S., Elmore, J.G., Projecting the benefits and harms of mammography using statistical models: proof or proofiness?. J Natl Cancer Inst, 107(7), 2015.
215. Lee, S., Zelen, M., Chapter 11: a stochastic model for predicting the mortality of breast cancer. JNCI Monogr 2006:36 (2006), 79–86.
216. Tan, S.Y.G.L., van Oortmarssen, G.J., de Koning, H.J., Boer, R., Habbema, J.D.F., Chapter 9: the MISCAN-Fadia continuous tumor growth model for breast cancer. JNCI Monogr 2006:36 (2006), 56–65.
217. van Ravesteyn, N.T., Miglioretti, D.L., Stout, N.K., Lee, S.J., Schechter, C.B., Buist, D.S., et al. Tipping the balance of benefits and harms to favor screening mammography starting at age 40 years: a comparative modeling study of risk. Ann Intern Med 156:9 (2012), 609–617.
218. Saadatmand, S., Tilanus-Linthorst, M.M., Rutgers, E.J., Hoogerbrugge, N., Oosterwijk, J.C., Tollenaar, R.A., et al. Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging. J Natl Cancer Inst 105:17 (2013), 1314–1321.
219. de Gelder, R., Fracheboud, J., Heijnsdijk, E.A., den Heeten, G., Verbeek, A.L., Broeders, M.J., et al. Digital mammography screening: weighing reduced mortality against increased overdiagnosis. Prev Med 53:3 (2011), 134–140.
220. Stout, N.K., Lee, S.J., Schechter, C.B., Kerlikowske, K., Alagoz, O., Berry, D., et al. Benefits, harms, and costs for breast cancer screening after US implementation of digital mammography. J Natl Cancer Inst, 106(6), 2014 dju092.
221. Tan, S.Y., van Oortmarssen, G.J., de Koning, H.J., Boer, R., Habbema, J.D., The MISCAN-Fadia continuous tumor growth model for breast cancer. J Natl Cancer Inst Monogr 36 (2006), 56–65.
222. van Oortmarssen, G.J., Habbema, J.D., van der Maas, P.J., de Koning, H.J., Collette, H.J., Verbeek, A.L., et al. A model for breast cancer screening. Cancer 66:7 (1990), 1601–1612.
223. Pisano, E.D., Gatsonis, C., Hendrick, E., Yaffe, M., Baum, J.K., Acharyya, S., et al. Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med 353:17 (2005), 1773–1783.
224. Ohuchi, N., Suzuki, A., Sobue, T., Kawai, M., Yamamoto, S., Zheng, Y.F., et al. Sensitivity and specificity of mammography and adjunctive ultrasonography to screen for breast cancer in the Japan Strategic Anti-cancer Randomized Trial (J-START): a randomised controlled trial. Lancet, 2015.
225. Haut, E.R., Pronovost, P.J., SUrveillance bias in outcomes reporting. JAMA 305:23 (2011), 2462–2463.
226. Kerlikowske, K., Hubbard, R.A., Miglioretti, D.L., Geller, B.M., Yankaskas, B.C., Lehman, C.D., et al. Comparative effectiveness of digital versus film-screen mammography in community practice in the United States: a cohort study. Ann Intern Med 155:8 (2011), 493–502.
227. Nie, K., Su, M.Y., Chau, M.K., Chan, S., Nguyen, H., Tseng, T., et al. Age- and race-dependence of the fibroglandular breast density analyzed on 3D MRI. Med Phys 37:6 (2010), 2770–2776.
228. Nederend, J., Duijm, L.E., Louwman, M.W., Groenewoud, J.H., Donkers-van Rossum, A.B., Voogd, A.C., Impact of transition from analog screening mammography to digital screening mammography on screening outcome in The Netherlands: a population-based study. Ann Oncol 23:12 (2012), 3098–3103.
229. Verschuur-Maes, A.H., van Gils, C.H., van den Bosch, M.A., De Bruin, P.C., van Diest, P.J., Digital mammography: more microcalcifications, more columnar cell lesions without atypia. Mod Pathol 24:9 (2011), 1191–1197.
230. Feeley, L., Kiernan, D., Mooney, T., Flanagan, F., Hargaden, G., Kell, M., et al. Digital mammography in a screening programme and its implications for pathology: a comparative study. J Clin Pathol 64:3 (2011), 215–219.
231. Hofvind, S., Skaane, P., Elmore, J.G., Sebuodegard, S., Hoff, S.R., Lee, C.I., Mammographic performance in a population-based screening program: before, during, and after the transition from screen-film to full-field digital mammography. Radiology 272:1 (2014), 52–62.
232. Kerlikowske, K., Hubbard, R.A., Tosteson, A.N., Higher mammography screening costs without appreciable clinical benefit: the case of digital mammography. JNatl Cancer Inst, 106(8), 2014.
233. Prummel, M.V., Done, S.J., Muradali, D., Majpruz, V., Brown, P., Jiang, H., et al. Digital compared to screen-film mammography: breast cancer prognostic features in an organized screening program. Breast Cancer Res Treat 147:2 (2014), 389–399.
234. Melnikow, J., Fenton, J.J., Whitlock, E.P., Miglioretti, D.L., Weyrich, M.S., Thompson, J.H., et al. Supplemental screening for breast cancer in women with dense breasts: a systematic review for the U.S. preventive services task force. Ann Intern Med, 2016.
235. Siu, A.L., U. S. Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 164:4 (2016), 279–296.
236. Houssami, N., Miglioretti, D.L., Digital breast tomosynthesis: a brave new world of mammography screening. JAMA Oncol 2:6 (2016), 725–727.
237. Health Quality Ontario, Ultrasound as an adjunct to mammography for breast cancer screening: a health technology assessment. Ont Health Technol Assess Ser 16:15 (2016), 1–71.
238. Brawley, O.W., Risk-based mammography screening: an effort to maximize the benefits and minimize the harms. Ann Intern Med 156:9 (2012), 662–663.
239. Nelson, H.D., Zakher, B., Cantor, A., Fu, R., Griffin, J., O'Meara, E.S., et al. Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. Ann Intern Med 156:9 (2012), 635–648.
240. Autier, P., Risk factors for breast cancer for women aged 40 to 49 years. Ann Intern Med, 157(7), 2012, 529 author reply 529.
241. Huo, C.W., Chew, G.L., Britt, K.L., Ingman, W.V., Henderson, M.A., Hopper, J.L., et al. Mammographic density-a review on the current understanding of its association with breast cancer. Breast Cancer Res Treat 144:3 (2014), 479–502.
242. Boyd, N.F., Rommens, J.M., Vogt, K., Lee, V., Hopper, J.L., Yaffe, M.J., et al. Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol 6:10 (2005), 798–808.
243. Chiu, S.Y., Duffy, S., Yen, A.M., Tabar, L., Smith, R.A., Chen, H.H., Effect of baseline breast density on breast cancer incidence, stage, mortality, and screening parameters: 25-year follow-up of a Swedish mammographic screening. Cancer Epidemiol Biomarkers Prev 19:5 (2010), 1219–1228.
244. Boyd, N.F., Martin, L.J., Sun, L., Guo, H., Chiarelli, A., Hislop, G., et al. Body size, mammographic density, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 15:11 (2006), 2086–2092.
245. Tice, J.A., O'Meara, E.S., Weaver, D.L., Vachon, C., Ballard-Barbash, R., Kerlikowske, K., Benign breast disease, mammographic breast density, and the risk of breast cancer. J Natl Cancer Inst 105:14 (2013), 1043–1049.
246. Tagliafico, A.S., Calabrese, M., Mariscotti, G., Durando, M., Tosto, S., Monetti, F., et al. Adjunct screening with tomosynthesis or ultrasound in women with mammography-negative dense breasts: interim report of a prospective comparative trial. J Clin Oncol, 2016.
247. Brower, V., Breast density legislation fueling controversy. J Natl Cancer Inst 105:8 (2013), 510–511.
248. Ozanne, E.M., Drohan, B., Bosinoff, P., Semine, A., Jellinek, M., Cronin, C., et al. Which risk model to use? Clinical implications of the ACS MRI screening guidelines. Cancer Epidemiol Biomarkers Prev 22:1 (2013), 146–149.
249. Warwick, J., Birke, H., Stone, J., Warren, R.M., Pinney, E., Brentnall, A.R., et al. Mammographic breast density refines Tyrer-Cuzick estimates of breast cancer risk in high-risk women: findings from the placebo arm of the International Breast Cancer Intervention Study I. Breast Cancer Res, 16(5), 2014, 451.
250. Easton, D.F., Pharoah, P.D., Antoniou, A.C., Tischkowitz, M., Tavtigian, S.V., Nathanson, K.L., et al. Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med 372:23 (2015), 2243–2257.
251. Schenberg, T., Mitchell, G., Taylor, D., Saunders, C., MRI screening for breast cancer in women at high risk; is the Australian breast MRI screening access program addressing the needs of women at high risk of breast cancer?. J Med Radiat Sci 62:3 (2015), 212–225.
252. Kriege, M., Brekelmans, C.T., Boetes, C., Besnard, P.E., Zonderland, H.M., Obdeijn, I.M., et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351:5 (2004), 427–437.
253. Narod, S.A., Screening of women at high risk for breast cancer. Prev Med 53:3 (2011), 127–130.
254. Chiarelli, A.M., Prummel, M.V., Muradali, D., Majpruz, V., Horgan, M., Carroll, J.C., et al. Effectiveness of screening with annual magnetic resonance imaging and mammography: results of the initial screen from the ontario high risk breast screening program. J Clin Oncol 32:21 (2014), 2224–2230.
255. Riedl, C.C., Luft, N., Bernhart, C., Weber, M., Bernathova, M., Tea, M.K., et al. Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density. J Clin Oncol 33:10 (2015), 1128–1135.
256. Mandelblatt, J.S., Cronin, K.A., Bailey, S., Berry, D.A., de Koning, H.J., Draisma, G., et al. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med 151:10 (2009), 738–747.
257. U. S. Preventive Services Task Force, Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 151:10 (2009), 716–726 W-236.
258. Nelson, H.D., Tyne, K., Naik, A., Bougatsos, C., Chan, B.K., Nygren, P., et al. Screening for breast cancer: systematic evidence review Update for the U. S. preventive services task force. 2009, Oregon Evidence-based practice center, Portland, Oregon.
259. Myers, E.R., Moorman, P., Gierisch, J.M., Havrilesky, L.J., Grimm, L.J., Ghate, S., et al. Benefits and harms of breast cancer screening: a systematic review. Jama 314:15 (2015), 1615–1634.
260. Harris, R.P., Helfand, M., Woolf, S.H., Lohr, K.N., Mulrow, C.D., Teutsch, S.M., et al. Current methods of the US preventive services task force: a review of the process. Am J Prev Med 20:3 Suppl (2001), 21–35.
261. Gotzsche, P.C., On the benefits and harms of screening for breast cancer. Int J Epidemiol 33:1 (2004), 56–64 discussion 69–73.
262. Carter, S.M., Rogers, W., Heath, I., Degeling, C., Doust, J., Barratt, A., The challenge of overdiagnosis begins with its definition. BMJ, 350, 2015 (mar04 2):h869–h869.
263. Norris, S.L., Burda, B.U., Holmer, H.K., Ogden, L.A., Fu, R., Bero, L., et al. Author's specialty and conflicts of interest contribute to conflicting guidelines for screening mammography. J Clin Epidemiol 65:7 (2012), 725–733.
264. American College of Radiology A, Acr practice parameter for the performance of screening and diagnostic mammography. 2016 http://www.acr.org/∼/media/ACR/Documents/PGTS/guidelines/Screening_Mammography.pdf.
265. Gotzsche, P.C., Jorgensen, K.J., The breast screening programme and misinforming the public. J R Soc Med 104:9 (2011), 361–369.
266. Baum, M., 'Catch it early, save a life and save a breast': this misleading mantra of mammography. J R Soc Med 108:9 (2015), 338–339.
267. Woloshin, S., Schwartz, L.M., How a charity oversells mammography. BMJ, 345, 2012, e5132.
268. Duffy, S.W., Tabar, L., Chen, T.H., Yen, A.M., Dean, P.B., Smith, R.A., What information should be given to women invited for mammographic screening for breast cancer?. Womens Health (Lond Engl) 2:6 (2006), 829–833.
269. Lin, K.W., Gostin, L.O., A public health framework for screening mammography: evidence-based vs politically mandated care. JAMA 315:10 (2016), 977–978.
270. Brawley, O., Byers, T., Chen, A., Pignone, M., Ransohoff, D., Schenk, M., et al. New American Cancer Society process for creating trustworthy cancer screening guidelines. Jama 306:22 (2011), 2495–2499.
271. American Cancer Society A, American Cancer Society recommendations for early breast cancer detection in women without breast symptoms. 2015 http://www.cancer.org/cancer/breastcancer/moreinformation/breastcancerearlydetection/breast-cancer-early-detection-acs-recs.
272. Oeffinger, K.C., Fontham, E.T.H., Etzioni, R., Herzig, A., Michaelson, J.S., Shih, Y.-C.T., et al. Breast cancer screening for women at average risk. Jama, 314(15), 2015, 1599.
273. Nelson, H.D., Pappas, M., Cantor, A., Griffin, J., Daeges, M., Humphrey, L., Harms of breast cancer screening: systematic review to update the 2009 U.S. Preventive Services Task Force Recommendation. Ann Intern Med 164:4 (2016), 256–267.
274. Barratt, A., Overdiagnosis in mammography screening: a 45 year journey from shadowy idea to acknowledged reality. BMJ, 350(mar03 14), 2015, h867.
275. Brawley, O.W., Accepting the existence of breast cancer overdiagnosis. Ann Intern Med 166:5 (2017), 364–365.
276. Esserman, L.J., Thompson, I.M., Reid, B., Nelson, P., Ransohoff, D.F., Welch, H.G., et al. Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol 15:6 (2014), e234–e242.
277. Paci, E., Broeders, M., Hofvind, S., Puliti, D., Duffy, S.W., Group tEW. European breast cancer service screening outcomes: a first balance sheet of the benefits and harms. Cancer Epidemiol Biomarkers Prev 23:7 (2014), 1159–1163.
278. Broeders, M., Moss, S., Nystrom, L., Njor, S., Jonsson, H., Paap, E., et al. The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies. J Med Screen 19:Suppl. 1 (2012), 14–25.
279. Wilson, J.M.G., Jungner, G., World Health Organization. Principles and practice of screening for disease. 1968, World Health Organization, Geneva, Switzerland.
280. Welch, H.G., Screening mammography–a long run for a short slide?. N Engl J Med 363:13 (2010), 1276–1278.